What is Intuitive Surgical's financial performance for the reported period?

For the third quarter ended September 30, 2000, Intuitive Surgical reported sales of $7.9 million, a 140% increase year-over-year. Despite this growth, the company reported a net loss of $4.0 million for the quarter. Gross profit margin improved substantially to 40% from 11% in the prior year's quarter. For the nine months ended September 30, 2000, sales were $15.9 million, up 130%, with a net loss of $13.5 million.

How has the company's cash position changed?

The company's cash and cash equivalents significantly increased to $25.9 million as of September 30, 2000, from $4.1 million at the end of 1999. This improvement is primarily attributed to the net proceeds of approximately $46.5 million raised from its initial public offering in June/July 2000, along with proceeds from warrant exercises.

What are the key drivers of revenue growth?

Revenue growth is primarily driven by the sales of the da Vinci Surgical System, a high-revenue product. The number of systems sold increased from 4 to 8 in the third quarter and from 8 to 17 in the first nine months of 2000 compared to the same periods in 1999. The company also expects to generate recurring revenue from the sale of instruments and accessories for installed systems.

What are the main risks and challenges facing Intuitive Surgical?

Key risks include the long and uncertain sales cycles for capital equipment, potential for significant quarterly revenue fluctuations due to a small customer base, the need for market acceptance of its novel surgical technology, lengthy and uncertain regulatory processes (though FDA clearance for laparoscopic procedures was obtained in July 2000), intense competition, and significant ongoing patent litigation with Computer Motion, Inc. The company also has a substantial accumulated deficit and expects continued losses in the near term.

ISRG 10-Q Quarterly Report Q3 FY2000 — Revenue, Net Income, EPS

Summary

Intuitive Surgical, Inc. (ISRG) reported its third-quarter and nine-month results for the period ending September 30, 2000. The company, a pioneer in robotic-assisted minimally invasive surgery with its da Vinci Surgical System, demonstrated significant year-over-year sales growth. For the third quarter, sales increased by 140% to $7.9 million compared to the prior year's $3.3 million, driven by an increase in da Vinci Surgical System placements from four to eight units. The nine-month sales also saw substantial growth, up 130% to $15.9 million from $6.9 million, with system placements growing from eight to seventeen. Despite robust top-line growth, the company continues to operate at a net loss, albeit with improving gross profit margins. Gross profit for the third quarter reached $3.2 million (40% of sales), a significant improvement from $0.4 million (11% of sales) in the same period last year, attributed to sales growth and manufacturing efficiencies. However, operating expenses, particularly R&D and SG&A, increased to support product development and sales expansion. The company ended the period with a strong cash position of $25.9 million, bolstered by its recent initial public offering (IPO) in June/July 2000, which raised approximately $46.5 million in net proceeds, along with earlier warrant exercises.

Key Highlights

1Sales revenue for Q3 2000 grew 140% year-over-year to $7.9 million, driven by an increase in da Vinci Surgical System sales from 4 to 8 units.
2Nine-month sales revenue increased 130% year-over-year to $15.9 million, with system sales growing from 8 to 17 units.
3Gross profit margin improved significantly to 40% in Q3 2000 from 11% in Q3 1999, reflecting sales growth and manufacturing efficiencies.
4The company continues to incur net losses, with a Q3 2000 net loss of $4.0 million, but operating expenses are increasing to support expansion.
5Cash and cash equivalents significantly increased to $25.9 million as of September 30, 2000, largely due to $46.5 million in net proceeds from the company's IPO in June/July 2000.
6The company received FDA clearance for commercialization of its da Vinci Surgical System in the U.S. for laparoscopic procedures in July 2000.
7Intuitive Surgical is involved in significant patent litigation with Computer Motion, Inc., concerning robotic surgery technology.

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2000

Summary

Key Highlights

Frequently Asked Questions